Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease

Histopathology

Volumn 28, Issue 1, 1996, Pages 1-13

  Bischoff, S C ^a   Wedemeyer, J ^a   Herrmann, A ^a   Meier, P N ^a   Trautwein, C ^a   Cetin, Y ^a   Maschek, H ^a   Stolte, M ^b   Gebel, M ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Crohn's disease; Eosinophils; Mast cells; Ulcerative colitis

Indexed keywords

CHYMASE; TRYPTASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; EOSINOPHIL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MAST CELL; MORPHOMETRICS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 9044219840     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.262309.x     Document Type: Article

References (49)

1. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest. 1990: 86; 1255-1260.
2. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992: 102; 529-537.
3. Weldon MJ, Maxwell JD. Lymphocyte and macrophage interleukin receptors in inflammatory bowel disease: a more selective target for therapy?. Gut 1994: 35; 867-871.
4. Seibold F, Weber P, Klein R, Berg PA, Wiedemann KH. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992: 33; 657-662.
5. Fox CC, Lichtenstein LM, Roche JK. Intestinal mast cell responses in idiopathic inflammatory bowel disease. Histamine release from human intestinal mast cells in response to gut epithelial proteins. Dig. Dis. Sci. 1993: 38; 1105-1112.
6. Crowe SE, Perdue MH. Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology. Gastroenterology 1992: 103; 1075-1095.
7. Metcalfe DD. Mast cell mediators with emphasis on intestinal mast cells. Ann. Allergy 1984: 53; 563-575.
8. Befus D, Goodacre R, Dyck N, Bienenstock J. Mast cell heterogeneity in man. Int. Arch. Allergy Appl. Immunol. 1985: 76; 232-236.
9. Dvorak AM. Utrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vivo: cytotoxic potential in Crohn's disease. J. Immunol. 1980: 125; 460-462.
10. Bischoff SC, Wedemeyer J, Wagner S, Meier PN, Manns MP. Human mast cells and basophils: new concepts and their relevance for the gastrointestinal tract. Z. Gastroenterol. 1994: 32; 64-70.
11. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N. Engl. J. Med. 1990: 323; 1033-1039.
12. Bradding P, Feather IH, Howarth PH et al. Interleukin 4 is localized to and released by human mast cells. J. Exp. Med. 1992: 176; 1381-1386.
13. Gauchat JF, Henchoz S, Mazzei G et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993: 365; 340-343.
14. Wong TW, Weller PF, Galli SJ et al. Human eosinophils express transforming growth factor α. J. Exp. Med. 1990: 172; 673-681.
15. Capron M, Capron A, Dessaint JP, Torpier G, Johansson SGO, Prin L. Fc receptors for IgE on human and rat eosinophils. J. Immunol. 1981; 126; 2087-2092.
16. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein 1 α induce the migration and activation of normal human eosinophil granulocytes. J. Exp. Med. 1992: 176; 1489-1495.
17. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ. IgA-induced eosinophil degranulation. J. Immunol. 1989; 142; 2333-2340.
18. Takafuji S, Bischoff SC, De Weck AL, Dahinden CA. Interleukin 3 and interleukin 5 prime human eosinophils to produce leukotriene C4 in response to soluble agonists. J. Immunol. 1991: 147; 3855-3861.
19. Bischoff SC, Dahinden CA. C-kit ligand: a unique potentiator of mediator release by human mast cells. J. Exp. Med. 1992: 175; 237-244.
20. Bischoff SC, Schwengberg S, Wordelmann K, Weimann A, Raab R, Manns MP. Effect of c-kit ligand, stem cell factor, on mediator release by human intestinal mast cells isolated from patients with inflammatory bowel disease. Gut 1996; in press.
21. Hällgren R, Colombel JF, Dahl R et al. Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunhistochemical localization of granulocyte granule constituents. Am. J. Med. 1989: 86; 56-64.
22. Knutson L, Ahrenstedt Ö, Odling B. Hällgren R. The jejunal secretion of histamine is increased in active Crohn's disease. Gastroenterology 1990: 98; 849-854.
23. Casellas F, Guarner F, Antolin M, Rodriguez R, Slas A, Malagelada JR. Abnormal leukotriene C4 release by unaffected jejunal mucosa in patients with inactive Crohn's disease. Gut 1994; 35: 517-522.
24. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990: 99; 119-124.
25. Marsh NM, Hinde J. Inflammatory component of celiac sprue mucosa. I. Mast cells, basophils, and eosinophils. Gastroenterology 1985: 89; 92-101.
26. Crowe SE, Perdue MH. Anti-immunoglobuline E-stimulated ion transport in human large and small intestine. Gastroenterology 1993: 105; 746-772.
27. Yamada T ed. Textbook of gastroenterology. Philadelphia: J. B. Lippincott Company, 1991.
28. Fenoglio-Preisser CM, Lantz PE, Listrom MB, Davis M, Rilke FO eds. Gastrointestinal pathology. New York: Raven Press, 1989.
29. Hiatt RB, Katz L. Mast cells in inflammatory conditions of the gastrointestinal tract. Am. J. Gastroenterol. 1962; 37; 541-545.
30. Ranlöv P, Nielsen MH, Wanstrup J. Ultrastructure of the ileum in Crohn's disease. Scand. J. Gastroenterol. 1972: 7; 471-476.
31. Bercovitz ZT, Sommers SC. Altered inflammatory reaction in nonspecific ulcerative colitis. Arch. Intern. Med. 1966: 117; 504-510.
32. Balazs M, Illyes G, Vadasz G. Mast cells in ulcerative colitis. Virchows Archiv B (Cell. Pathol.) 1989: 57; 353-360.
33. Sanderson IR, Leung KBP, Pearce FL, Walker-Smith JA. Lamina propria mast cells in biopsies from children with Crohn's disease. J. Clin. Pathol. 1986; 39; 279-283.
34. Dvorak AM, Monahan RA. Crohn's disease - mast cell quantitation using one micron plastic sections for light microscopy. Pathol. Annu. 1983: 18; 181-190.
35. Sarin SK, Malhotra V, Sen Gupta S, Karol A, Gaur SK, Anand BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis - a prospective controlled study. Dig. Dis. Sci. 1987: 32; 363-367.
36. Lloyd G, Green FHY, Fox H, Mani V, Turnberg LA. Mast cells and immunoglobulin E in inflammatory bowel disease. Gut 1975: 16; 861-866.
37. King T, Biddle W, Bhatia P, Moore J, Miner PB. Colonic mucosal must cell distribution at line demarcation of active ulcerative colitis. Dig. Dis. Sci. 1992; 37; 490-495.
38. Strobel S, Miller HRP, Ferguson A. Human intestinal mucosal mast cells; evaluation of fixation and staining techniques. J. Clin. Pathol. 1981: 34; 851-858.
39. Dhesi I, Marsh MN, Kelly C, Crowe P. Morphometric analysis of small intestinal mucosa. Virchows Archiv A (Pathol. Anat.) 1984: 403; 173-180.
40. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulfulazine in the treatment of active ulcerative colitis: a randomised trial. Br. Med. J. 1989: 298; 82-86.
41. Best WR, Becktel JM, Singleton JW, Kern R. Development of a Crohn's disease activity index. Gastroenterology 1976; 70; 439-444.
42. TC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J. Histochem. Cytochem. 1989: 37; 1509-1515.
43. Norris HT, Zamcheek N, Gottlieb LS. The presence and distribution of mast cells in the human gastrointestinal tract. Gastroenterology 1963: 44; 448-458.
44. Goldsmith P, McGarity B, Walls AF, Church MK, Millward-Sadler GH, Robertson DAF. Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig. Dis. Sci. 1990: 35; 1409-1413.
45. Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. Inflammatory cells and eosinophil activity in asthmatics investigated by bronchoalveolar lavage; the effects of antiasthmatic treatments with budesonide or terbutaline. Am. Rev. Respir. Dis. 1990: 142; 91-99.
46. Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J. Immunol. 1991: 147; 254-259.
47. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. Path. Res. Pract. 1993: 189; 156-162.
48. Irani AA, Craig SS, DeBlois G, Elson CO, Schlechter NM, Schwartz LB. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J. Immunol. 1987: 138; 4381-4386.
49. Tsai M, Shih LS, Newlands FJ et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J. Exp. Med. 1991: 174; 125-131.